We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum antivenom for snakebites. Conventional antivenom is outdated: it's expensive, labor-intensive, works for a single species of snake, can only be administered in a hospital, must be kept cold, and has a host of negative side effects for the patient. Our first product, Vipax, elegantly solves these problems while being cheaper to produce. [Read More]
A safe is a Simple Agreement for Future Equity. An investor makes a cash investment in a company, but gets company stock at a later date, in connection with a specific event. A safe is not a debt instrument, but is intended to be an alternative to convertible notes that is beneficial for both companies and investors.
February 23, 2019
March 31, 2019
Open to Investors
Intermediary Fee: 5%
Manufacturing of Product: 45%
Pre-Clinical Testing: 50%
Daniel Dempsey - Founder & CEO
Extensive background in developing antibody drugs and bringing to market. MS Biomedical from UCSD.
Deepankar Roy - Co-founder & COO
Expertise in antibody engineering, Genentech. PhD in Biochem and Molecular Bio from USC.
First $75K investors of this fundraise will invest in a SAFE with a $4M valuation cap and 15% discount.
$25K+ pro rata right threshold